PALISADE BIO, INC. (PALI) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 12.90M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -35.35M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $12.90M | $-35.35M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $8.18M | $-26.49M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $3.96M | $-18.06M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | (m) | $305.00K | $-11.46M | $11.00K | (m) | (m) | -1041.55× | Reported |
| 2025-06-30 | (m) | (m) | $310.00K | $-12.13M | $12.00K | (m) | (m) | -1010.67× | Reported |
| 2025-03-31 | (m) | (m) | $603.00K | $-13.50M | $12.00K | (m) | (m) | -1124.67× | Reported |
| 2024-12-31 | (m) | $0.00 | $652.00K | $-14.86M | $12.00K | (m) | (m) | -1238.25× | Reported |
| 2024-09-30 | (m) | $0.00 | $760.00K | $-14.63M | $13.00K | (m) | (m) | -1125.46× | Reported |
| 2024-06-30 | (m) | $0.00 | $867.00K | $-14.82M | $15.00K | (m) | (m) | -987.73× | Reported |
| 2024-03-31 | (m) | $0.00 | $649.00K | $-14.21M | $16.00K | (m) | (m) | -888.38× | Reported |
| 2023-12-31 | (m) | $250.00K | $624.00K | $-13.07M | $15.00K | (m) | 249.60% | -871.33× | Reported |
| 2023-09-30 | (m) | (m) | $525.00K | $-13.76M | $14.00K | (m) | (m) | -983.14× | Reported |
| 2023-06-30 | (m) | (m) | $575.00K | $-14.40M | $10.00K | (m) | (m) | -1439.90× | Reported |
| 2023-03-31 | (m) | (m) | $767.00K | $-14.36M | $12.00K | (m) | (m) | -1196.83× | Reported |
| 2022-12-31 | (m) | (m) | $1.03M | $-15.72M | $13.00K | (m) | (m) | -1209.31× | Reported |
| 2022-09-30 | (m) | (m) | $1.63M | $-15.90M | $15.00K | (m) | (m) | -1060.00× | Reported |
| 2022-06-30 | (m) | (m) | $1.52M | $-14.50M | $37.00K | (m) | (m) | -391.97× | Reported |
| 2022-03-31 | (m) | (m) | $1.68M | $-43.79M | $688.00K | (m) | (m) | -63.65× | Reported |
| 2021-12-31 | (m) | (m) | $1.89M | $-41.85M | $2.40M | (m) | (m) | -17.45× | Reported |
| 2021-09-30 | (m) | (m) | $248.99K | $-42.45M | $2.37M | (m) | (m) | -17.93× | Reported |
| 2021-06-30 | (m) | (m) | $768.99K | $-41.25M | $2.37M | (m) | (m) | -17.41× | Reported |
| 2021-03-31 | $1.79M | (m) | $757.09K | $-10.88M | $13.01K | (m) | (m) | -836.28× | Reported |
| 2020-12-31 | $2.02M | (m) | $584.99K | $-10.68M | $14.02K | (m) | (m) | -761.72× | Reported |
| 2020-09-30 | $2.38M | (m) | $643.41K | $-8.41M | $18.50K | (m) | (m) | -454.86× | Reported |
| 2020-06-30 | $2.74M | (m) | $731.18K | $-8.19M | $16.82K | (m) | (m) | -487.05× | Reported |
| 2020-03-31 | $3.24M | (m) | $618.72K | $-8.17M | $9.48K | (m) | (m) | -861.17× | Reported |
| 2019-12-31 | $4.06M | (m) | $880.79K | $-8.63M | $8.92K | (m) | (m) | -967.68× | Reported |
| 2019-09-30 | $4.17M | (m) | $825.15K | $-8.30M | $7.95K | (m) | (m) | -1045.18× | Reported |
| 2019-06-30 | $4.24M | (m) | $665.25K | $-8.26M | $7.53K | (m) | (m) | -1097.27× | Reported |
| 2019-03-31 | $4.31M | (m) | $733.21K | $-8.37M | $7.79K | (m) | (m) | -1073.38× | Reported |
| 2018-12-31 | $3.96M | (m) | $634.08K | $-8.26M | $7.70K | (m) | (m) | -1072.94× | Reported |
| 2018-09-30 | $4.31M | (m) | $836.09K | $-8.72M | $7.41K | (m) | (m) | -1176.80× | Reported |
| 2018-06-30 | $4.79M | (m) | $1.03M | $-9.23M | $7.30K | (m) | (m) | -1264.57× | Reported |
| 2018-03-31 | $6.36M | (m) | $1.49M | $-11.42M | $22.25K | (m) | (m) | -513.35× | Reported |
| 2017-12-31 | $8.10M | $260.00K | $1.77M | $-13.31M | $159.07K | 3113.88% | 680.76% | -83.66× | Reported |
| 2017-09-30 | $10.90M | $16.25K | $2.08M | $-16.69M | $347.76K | 67074.38% | 12821.06% | -47.99× | Reported |
| 2017-06-30 | $13.10M | $16.25K | $2.33M | $-19.02M | $586.84K | 80652.67% | 14354.14% | -32.41× | Reported |
| 2017-03-31 | $12.99M | $16.25K | $2.50M | $-18.64M | $893.52K | 79972.81% | 15370.50% | -20.86× | Reported |
| 2016-12-31 | $13.16M | $16.25K | $3.45M | $-20.64M | $1.14M | 80979.24% | 21208.54% | -18.08× | Reported |
| 2016-09-30 | $11.88M | $10.00K | $3.70M | $-19.34M | $1.39M | 118795.40% | 36970.91% | -13.93× | Reported |
| 2016-06-30 | $11.68M | $10.00K | $3.92M | $-19.62M | $1.61M | 116818.33% | 39235.03% | -12.17× | Reported |
| 2016-03-31 | $12.52M | $10.00K | $3.73M | $-20.78M | $1.75M | 125200.45% | 37323.96% | -11.88× | Reported |
| 2015-12-31 | $12.64M | $10.42K | $2.95M | $-19.16M | $1.82M | 121313.99% | 28332.22% | -10.55× | Reported |
| 2015-09-30 | $12.27M | $12.58K | $2.80M | $-19.45M | $1.81M | 97548.92% | 22269.33% | -10.77× | Reported |
| 2015-06-30 | $11.00M | $15.08K | $2.65M | $-18.36M | $1.70M | 72930.66% | 17595.07% | -10.78× | Reported |
| 2015-03-31 | $9.69M | $17.58K | $2.57M | $-16.87M | $1.64M | 55094.19% | 14610.31% | -10.28× | Reported |
| 2014-12-31 | $8.13M | $18.83K | $4.32M | $-17.44M | $1.62M | 43194.14% | 22938.85% | -10.76× | Reported |
| 2014-09-30 | $7.21M | $16.67K | $3.89M | $-15.56M | $1.65M | 43257.98% | 23337.33% | -9.43× | Reported |
| 2014-06-30 | $7.00M | $14.17K | $4.24M | $-15.08M | $1.74M | 49398.93% | 29929.69% | -8.68× | Reported |
| 2014-03-31 | $6.96M | $11.67K | $4.30M | $-14.81M | $1.78M | 59631.22% | 36819.14% | -8.33× | Reported |
| 2013-12-31 | $7.13M | $110.00K | $2.33M | $-12.52M | $1.39M | 6485.73% | 2119.46% | -8.98× | Reported |
| 2013-09-30 | $7.20M | $110.00K | $2.50M | $-12.49M | $937.38K | 6546.89% | 2276.27% | -13.32× | Reported |
| 2013-06-30 | $6.74M | $278.33K | $1.98M | $-11.44M | $488.77K | 2421.44% | 712.51% | -23.40× | Reported |
| 2013-03-31 | $6.43M | $353.96K | $1.72M | $-10.59M | $50.10K | 1817.16% | 485.16% | -211.27× | Reported |
| 2012-12-31 | $6.11M | $407.71K | $1.61M | $-10.16M | $2.70K | 1497.64% | 395.10% | -3763.04× | Reported |
| 2012-09-30 | $5.81M | $692.42K | $1.65M | $-9.99M | $2.61K | 839.49% | 237.73% | -3828.22× | Reported |
| 2012-06-30 | $6.55M | $625.00K | $1.83M | $-10.63M | $2.27K | 1048.24% | 292.32% | -4673.22× | Reported |
| 2012-03-31 | $7.04M | (m) | $2.55M | $-11.92M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $7.35M | $390.63K | $3.33M | $-12.99M | $821.00 | 1882.84% | 853.27% | -15822.74× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $9.16M | $733.44K | $5.24M | $-15.18M | $2.66K | 1249.43% | 714.56% | -5704.31× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $5.35M | (m) | $4.56M | $-10.47M | $776.00 | (m) | (m) | -13487.82× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |